β-amyloid related disease
Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease
... relationship between the levels of Aβ oligomers in the plasma and other AD biomarkers. The diagnostic per- formance of measuring plasma levels of the Aβ oligo- mers by MDS was also comparable with that of other ...
10
Cerebral amyloid angiopathy-related inflammation: a case report presenting with a rare variant in SORL1 gene
... to β-amyloid (Aβ) protein in the blood vessel walls [5] and likely responsive to corticosteroid or other immunosuppres- sive agents ...9]. Amyloid-related imaging abnormalities (ARIA) ...
6
Prophylactic melatonin significantly reduces Alzheimer’s neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPPswe/PS1 mice
... A β : Amyloid-beta; A β PP swe : Amyloid-beta precursor protein, human Swedish mutation; AD: Alzheimer ’ s disease; C3B6: Mice with a combination C3H/He and C57BL/6 background; CAT: ...
21
Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease
... pE3-A β in core plaques was the only feature observed in the majority of both AD and ...was related to intraneuronal pE3-Aβ, which was limited to few OC cases while present in 52% of ...pE3-A β might ...
10
Cross-talk of membrane lipids and Alzheimer-related proteins
... s disease (AD) is neuropathologically characterized by the combined occurrence of extracellular β - amyloid plaques and intracellular neurofibrillary tangles in the ...the amyloid β ...
12
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
... A β : Amyloid β ; AD: Alzheimer ’ s disease; AIC: Akaike information criterion; BACE1: β -secretase 1; CRP: C-reactive protein; CSF: Cerebrospinal fluid; FGF: Fibroblast growth factor; ...
8
Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort
... A β : Amyloid- β ; AD: Alzheimer ’ s disease; ADNI: Alzheimer ’ s Disease Neuroimaging Initiative; ADRD: Alzheimer ’ s disease and related disorders; aMCI: Amnestic mild ...
13
Deciphering the genesis and fate of amyloid β protein yields novel therapies for Alzheimer disease
... atherosclerotic disease, would include inquiry about a positive family history of AD or a related demen- tia, identification of specific predisposing genetic fac- tors, structural and functional brain ...
8
Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease
... Alzheimer’s disease (AD) is the most common age- related neurodegenerative disorder, currently aff ecting 20 to 30 million individuals worldwide ...the disease is progressive memory loss due to the ...
14
Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
... s disease; APOE: Apolipoprotein E; ARMWS: Age-related white matter changes scale; A β : Amyloid- β ; BBACL: BioBank Alzheimer Center Limburg; CSF: Cerebrospinal fluid; CVD: ...
10
Calcium/calmodulin-dependent kinase II and Alzheimer’s disease
... Alzheimer’s disease (AD) is characterised by progressive loss of selective cognitive functions, particularly those related to ...aggregated amyloid-β (Aβ) peptides [2–4] and ...
7
Mitochondrial β amyloid in Alzheimer's disease
... Aβ, amyloid-beta peptide; ABAD, amyloid-binding alcohol dehydrogenase; AD, Alzheimer’s disease; ANT, adenine nucleotide translocase; Cdk5, cyclin-dependent kinase 5; CHANA, cyclohexenyl amine ...
11
The Alzheimer’s disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway
... containing β-mercaptoethanol (1% v/v) and bromophenol blue ...against β -actin (1:25000 dilution), followed by 30 min incubation at RT with sec- ondary goat anti-mouse ...
13
APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment
... A β : Amyloid β ; AD: Alzheimer ’ s disease; APLP1: Amyloid-like protein 1; APP: Amyloid precursor protein; CSF: Cerebrospinal fluid; GSM: γ -Secretase modulator; MALDI-TOF/TOF: Matrix-a[r] ...
10
Decreasing the expression of PICALM reduces endocytosis and the activity of β secretase: Implications for Alzheimer's disease
... by β-secretase after deple- tion of PICALM probably due to less APP being endo- cytosed into early endosomes to encounter ...of β-secretase itself is respon- sible for the effects of PICALM and clathrin ...
17
Download Download PDF
... IMUNOLOŠKI ASPEKTI I ANTIAMILOIDNE STRATEGIJE ZA ALZHEIMEROVU DEMENCIJU Alzheimerova bolest (AB) najučestaliji je oblik demencije u starijih: najmanje dvije trećine sveukupnih slučajeva demencija upravo je AB. ...
6
Cell adhesion molecules in Alzheimer's disease
... in amyloid-β (Aβ) metabolism, cell plasticity, neuroinflammation, and vascular changes, all of which are considered central to the pathogenesis and progression of Alzheimer’s disease ...
13
Adult hippocampal neurogenesis and its role in Alzheimer's disease
... Alzheimer’s disease (AD), first described by the German neuropathologist Alois Alzheimer as Dementia Praecox in 1907, is an age-related neurodegenerative disease characterized by progressive loss of ...
9
Apolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factors
... The neuroinflammagenic potential of IL-1b is shown here through its induction of synthesis of itself and other proinflammatory cytokines including TNF, IL-1a, IL-1b, as well as the latter’s maturation enzyme ICE. The ...
12
Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs
... (the β-secretase site) as well as the β’-site (between E10 and V11), while BACE2 preferentially cleaves APP within the Aβ region between F19 and F20 or between F20 and A21 [18, 73, 77, ...
11